Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Federica Sora', Roberto Latagliata, Massimo Breccia, Fausto Castagnetti, Fabio Stagno, Luigiana Luciano, Antonella Gozzini, Stefano Ulisciani, Francesco Cavazzini, Mario Annunziata, Antonella Russo Rossi, Patrizia Pregno, Enrico Montefusco, Elisabetta Abruzzese, Elena Crisà, Pellegrino Musto, Mario Tiribelli, Gianni Binotto, Ubaldo Occhini, Costanzo FeoPaolo Vigneri, Valeria Santini, Carmen Fava, Giannantonio Rosti, Giuliana Alimena

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

30 Citazioni (Scopus)

Abstract

To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0% vs 19.6%, p=0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140 mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects.
Lingua originaleEnglish
pagine (da-a)1164-1169
Numero di pagine6
RivistaLeukemia Research
Volume35
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Aged
  • Antineoplastic Agents
  • Drug Resistance, Neoplasm
  • Drug Tolerance
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Male
  • Middle Aged
  • Pyrimidines
  • Retrospective Studies
  • Thiazoles
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib'. Insieme formano una fingerprint unica.

Cita questo